Moreover, the SUMMIT trial [30] recently showed that tirzepatide, a dual GLP-1/GIP receptor agonist, significantly reduced the risk of cardiovascular death or HF worsening and improved quality of life in patients with HFpEF and obesity. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.